Skip to main content
Download PDF

Surfactant protein A genetic variants associate with severe respiratory insufficiency in pandemic influenza A virus infection

Critical Care volume 18, Article number: R127 (2014) Cite this article

Abstract

Introduction

Inherited variability in host immune responses influences susceptibility and outcome of Influenza A virus (IAV) infection, but these factors remain largely unknown. Components of the innate immune response may be crucial in the first days of the infection. The collectins surfactant protein (SP)-A1, -A2, and -D and mannose-binding lectin (MBL) neutralize IAV infectivity, although only SP-A2 can establish an efficient neutralization of poorly glycosylated pandemic IAV strains.

Methods

We studied the role of polymorphic variants at the genes of MBL (MBL2), SP-A1 (SFTPA1), SP-A2 (SFTPA2), and SP-D (SFTPD) in 93 patients with H1N1 pandemic 2009 (H1N1pdm) infection.

Results

Multivariate analysis showed that two frequent SFTPA2 missense alleles (rs1965708-C and rs1059046-A) and the SFTPA2 haplotype 1A0 were associated with a need for mechanical ventilation, acute respiratory failure, and acute respiratory distress syndrome. The SFTPA2 haplotype 1A1 was a protective variant. Kaplan-Meier analysis and Cox regression also showed that diplotypes not containing the 1A1 haplotype were associated with a significantly shorter time to ICU admission in hospitalized patients. In addition, rs1965708-C (P = 0.0007), rs1059046-A (P = 0.0007), and haplotype 1A0 (P = 0.0004) were associated, in a dose-dependent fashion, with lower PaO2/FiO2 ratio, whereas haplotype 1A1 was associated with a higher PaO2/FiO2 ratio (P = 0.001).

Conclusions

Our data suggest an effect of genetic variants of SFTPA2 on the severity of H1N1pdm infection and could pave the way for a potential treatment with haplotype-specific (1A1) SP-A2 for future IAV pandemics.

Introduction

Influenza A virus (IAV) infection is usually a mild and self-limited condition. Likewise, infection with the H1N1 pandemic 2009 (H1N1pdm) IAV often results in an uncomplicated flu, but, in a small subset of patients, it may rapidly evolve to primary viral pneumonia, acute respiratory failure (ARF), and acute respiratory distress syndrome (ARDS) [1]. Inherited and acquired variability in host immune responses may influence susceptibility and outcome of IAV infection, although these factors remain largely unknown [2–4].

Before exposure to H1N1pdm IAV, most individuals, particularly those born after 1957, lack serum antibodies capable of neutralizing the virus [1]. Adaptive immune responses, which are needed for ultimate viral clearance, take several days to develop. Therefore, components of the innate immunity that are able to neutralize IAV infection with minor inflammation may be crucial for host defense in the first few days after infection. Different soluble pattern-recognition molecules of the innate immunity can neutralize IAV infection. Several secreted human C-type lectins of the collectin family, the serum mannose-binding lectin (MBL), the pulmonary surfactant proteins (SP) –A1, –A2, and –D, and collectin 11 (CL-11, alias collectin kidney 1, CL-K1) may neutralize IAV infectivity in vitro[5–8]. Among these collectins, the SPs have been shown to exert an important role against IAV infection in animal models: mice lacking SP-A or SP-D have increased susceptibility to IAV infection, and their role seem to depend on IAV strains, particularly pandemic versus seasonal strains [9–14]. In addition, variability at the collectin genes, MBL2 (Ensembl: ENSG00000165471), SFTPA1 (Ensembl: ENSG00000122852), SFTPA2 (Ensembl: ENSG00000185303), and SFTPD (Ensembl: ENSG00000133661) have been found to be associated with susceptibility to and/or severity of several bacterial and viral infectious diseases [6, 15].

It hence follows that these collectins are firm candidates to explain, at least in part, the role of host genetic variability in the defense against IAV infection. The human SP-A locus consists of two similar genes, SFTPA1 and SFTPA2, localized within a cluster (10q21-24) that includes the SP-D gene (SFTPD) [16]. MBL2 was reported not to be in physical linkage with the genes of these SPs [17], but linkage disequilibrium of MBL2 with SFTPA1 and SFTPA2 has been shown; and LD among variants at these genes could influence the results of genetic-association studies [6, 18, 19].

In the present study, we assessed the role of variants at the SFTPA1, SFTPA2, and SFTPD genes in H1N1pdm IAV infection in humans. Variants at the neighbor collectin gene MBL2 were also analyzed.

Materials and methods

H1N1pdm-infected patients

We recruited 124 patients with H1N1pdm infection between July 2009 and November 2011. Thirty-one individuals with ancestors other than Spanish were excluded. Of 93 unrelated white Spanish patients, 70 were hospitalized at five tertiary Spanish hospitals, and 23 were attended at primary care centers (Figure 1). Data and samples from all ambulatory patients and from 30% of hospitalized individuals were retrospectively obtained; in the remaining patients, data were obtained prospectively. All patients were treated with oseltamivir, and only one patient had been previously vaccinated against H1N1pdm.

Figure 1
figure 1

Selection process for patients with H1N1pdm 2009 infection. Infection by H1N1pdm was confirmed in all the 124 patients.

Full size image

Diabetes, previous lung disease, solid-organ transplantation, immunosuppression, body mass index (BMI) ≥30, human immunodeficiency virus (HIV) infection, and pregnancy were considered risk factors. Sepsis, septic shock, and multiorgan dysfunction syndrome (MODS) were defined by using the American College of Chest Physicians/Society of Critical Care Medicine criteria [20]. ARF and ARDS were diagnosed according to the American European Consensus Conference Definition [21]. Functional parameters of gas exchange were calculated on the basis of the ratio of oxygen arterial pressure to oxygen inspiratory fraction (PaO2/FiO2). In hospitalized patients without arterial blood gas analysis (n = 18), ARF was established when hemoglobin oxygen saturation, breathing room air, was lower than 90%. In patients with intensive care unit (ICU) admission, severity of illness was evaluated with the Acute Physiology and Chronic Health Evaluation II score, taking the worst reading of the first 24 hours in the ICU.

All steps were performed in complete accordance to the Helsinki declaration. The protocol was approved by Clinical Research Ethics Committees (CEIC) of hospitals involved (CEIC Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria; CEIC Hospital San Jorge, Huesca and CEIC Hospital Clínico y Universitario de Valencia, Valencia). Informed consent was obtained of all patients included.

Detection of H1N1pdm by real-time polymerase chain reaction

Influenza A H1N1 virus in the 124 patients was detected in nasopharyngeal swabs by using the Real-Time ready Influenza A (H1N1) Detection Set (Roche Diagnostics GmbH, Mannheim, Germany) according to manufacturer’s protocol.

General Spanish-population subjects

The general population group consisted of white unrelated Spanish healthy volunteers (blood and bone marrow donors as well as hospital staff) from four tertiary Spanish hospitals. The control group was analyzed for MBL2 (n = 1,736) and SFTPA1 and SFTPA2 (n = 769) polymorphisms in previous studies [18, 19]. For the nine SFTPD variants under study, 963 individuals from the general population group recruited at the same hospitals were analyzed in this study. The protocol was approved by Clinical Research Ethics Committees (CEIC) of hospitals involved (CEIC Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria; CEIC Hospital de la Princesa, Madrid; CEIC Hospital San Jorge, Huesca and CEIC Hospital Clínico y Universitario de Valencia, Valencia). Informed consent was obtained of the general-population individuals included. No data about whether individuals from the general Spanish population group were or were not infected with H1N1pdm were available. Foreigners and individuals with ancestors other than Spanish were previously excluded.

Selection of single-nucleotide polymorphisms

Deficient and low MBL serum levels are mainly due to the presence of three common point mutations in the exon 1 of the MBL2 gene: alleles B (rs1800450), C (rs1800451), and D (rs5030737) are termed O alleles, A being the wild-type. Serum MBL levels are very low or absent in individuals homozygous for O alleles. In addition, the presence of the promoter allele X (rs7096206) has an important downregulating effect, and individuals with XA/O also have very low MBL serum levels. O/O together with XA/O genotypes are considered MBL-deficient genotypes, which are common in most populations.

The human SP-A locus consists of two similar genes, SFTPA1 and SFTPA2, located on chromosome 10q22.3, within a cluster that includes the SP-D gene (SFTPD). In addition, a certain degree of linkage disequilibrium (LD) exists among SP genes and the MBL gene (10q21-24) [18, 19]. On the basis of the existence of several SNPs, SP-A haplotypes are conventionally denoted as 6An for the SFTPA1 gene (V19A, rs1059047; L50V, rs1136450; R219W, rs4253527) and 1An for the SFTPA2 gene (T9N, rs1059046; A91P, rs17886395; Q223K, rs1965708) [22]. These missense single-nucleotide polymorphisms (SNPs) at SFTPA1 and SFTPA2 were analyzed in our study. The most frequent conventional haplotypes of these genes, except 1A and 1A5, can be unambiguously identified.

For the analysis of SFTPD, genotypic data of individuals of European ancestry (CEU) from the International HapMap Project [23] were used to select LD tagging SNPs. Pairwise LD-tagging was achieved with Haploview v. 4.2 [24] for SNPs with a minimum minor allele frequency of 0.05 and r2 of 0.8. As result, three intronic SNPs (rs10887199, rs7078012, and rs723192) and one synonymous SNP (rs6413520) were selected. Three missense SNPs were also analyzed: rs3088308 (S290T), rs2243639 (T180A), and rs721917 (M31T). Additionally, we studied an SNP in the SFTPD promoter region (rs1885551) that was recently reported to have a profound impact on serum SP-D levels [25] and an intronic SNP (rs17886286) associated with susceptibility to invasive pneumococcal disease [26].

DNA extraction and genotyping

Genomic DNA was extracted from 400 μl of peripheral blood by using iPrep PureLink gDNA Blood kit in the iPrep Purification Instrument (Invitrogen by Life Technologies, Carlsbad, CA, USA). Extracted DNA integrity was checked by NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA). In total, 19 polymorphisms at MBL2, SFTPA1, SFTPA2 and SFTPD were studied.

MBL2, SFTPA1, SFTPA2, and SFTPD rs721917 SNPs were analyzed by means of PCR-RFLP and PCR-SSP techniques, as previously described [18, 19]. The other eight SNPs of SFTPD were determined by predesigned Taqman SNP genotyping assays (Assays IDs: C__26726209_10, C__26726205_10, C__31530298_10, C__63652102_10, C__29213175_10, C___1362981_20, C____630297_10, and C__12124527_20), according to the manufacturer’s protocol, with commercially available reagents by means of ViiA™7 Real-time PCR System (Applied Biosystems, Foster City, CA, USA).

Data analysis

The Hardy-Weinberg equilibrium was analyzed with Haploview v. 4.2. Haplotypes were estimated in silico with PHASE v. 2.1.1 under 1,000 permutations. Statistical analyses were performed by using SPSS 20.0 (SPSS, Inc., Chicago, IL, USA). The comparison of all genotype distributions based on susceptibility and severity was performed by using the χ2 test or Fisher Exact test when needed, and odds ratios with 95% confidence intervals were calculated. The relation between severity in hospitalized patients and genotypes was evaluated by binary logistic regression models: age, gender, risk factors, and secondary infection (either bacteremia or secondary bacterial pneumonia) were included as independent variables.

Comparison of the PaO2/FiO2 ratio according to genetic variants was performed by a using linear regression model adjusted by age, gender, risk factors, and secondary infection (either bacteremia or secondary bacterial pneumonia).

To assess the need for ICU admission, a multivariate analysis was performed, including the aforementioned variables, by conditional logistic regression stratified by hospital of origin.

Log-rank (LR) χ2 tests were calculated to compare ICU admission according to the distribution of genetic variants. Cox proportional hazard ratios adjusted for the independent variables age, gender, risk factors, development of secondary bacterial infection (pneumonia or bacteremia), and hospital of origin were also performed.

Results

Demographic and clinical characteristics of patients are shown in Table 1. The genotype distribution of SNPs did not differ significantly under conditions of Hardy-Weinberg equilibrium in all of the groups studied (data not shown). Frequencies of the genetic variants under analysis were not found to be significantly different between H1N1pdm-infected patients and the general population (Table 2).

Table 1 Demographic and clinical characteristics of H1N1pdm-infected patients
Full size table
Table 2 Distribution of genotype frequencies of collectin genes in general Spanish population and H1N1pdm-infected patients
Full size table

When severity of infection was evaluated in hospitalized patients (n = 70) (Table 3), we observed that two missense variants at SFTPA2 (rs1965708-C and rs1059046-A) were significantly associated with the need for mechanical ventilation (MV) and with development of ARF and ARDS. Most of these associations remained significant after multivariate analysis adjusted for age, gender, risk factors, and secondary infection (either bacteremia or secondary bacterial pneumonia). The alleles rs1965708-C and rs1059046-A were overrepresented in patients requiring MV (P = 0.003; OR, 2.43; and P = 0.016; OR, 3.71, respectively), and in those who developed ARF (P = 0.006; OR, 4.09; and P = 0.005; OR, 3.70, respectively) or ARDS (P = 0.006; OR, 17.68; and P = 0.016; OR, 3.71, respectively). The variant rs1965708-C was also associated with septic shock (P = 0.007; OR, 17.16). The SFTPA1 allele rs1136450-G was also associated, although to a lower extent, with the development of ARF (P = 0.038; OR, 2.64) and the use of MV (P = 0.040; OR, 2.55); these associations may be secondary to the existence of LD between SFTPA1 and SFTPA2 variants (Figure 2).

Table 3 Severity of H1N1pdm infection in hospitalized patients regarding missense single-nucleotide polymorphisms of SFTPA2 and SFTPA1
Full size table
Figure 2
figure 2

Linkage disequilibrium (D’) among genetic polymorphisms of surfactant proteins in general Spanish population ( N = 687). LD plots for pair wise Dʹ between markers and Dʹ values are indicated in percentages within squares in the LD plot. Strong LD is indicated by dark gray/red, whereas light gray/pink and white indicate uninformative and low confidence values, respectively.

Full size image

When haplotypes, based on combinations of missense SNP, were analyzed (Table 4), the SFTPA2 haplotype 1A0 was found to be associated with the need for MV and with the development of ARF and ARDS in hospitalized patients. These differences were found to be independent of age, gender, risk factors, and secondary infection (either bacteremia or secondary bacterial pneumonia) in multivariate analysis: P = 0.003 (data in Table 4), OR 3.73; P = 0.022; OR, 2.81; and P = 0.016; OR, 3.41, for the need for MV, ARF, and ARDS comparisons, respectively. By contrast, the SFTPA2 haplotype 1A1 was found to be protective in a dominant model against the requirement for MV and the development of ARF and ARDS in the multivariate analysis (P = 0.015; OR, 0.16; P = 0.005; OR, 0.21; and P = 0.021; OR, 0.12).

Table 4 Severity of H1N1pdm infection in hospitalized patients regarding haplotypes of SFTPA2
Full size table

As an additional measurement of severity, we analyzed the need for ICU admission in hospitalized patients. The variants rs1965708-C and rs1059046-A were associated with a higher rate of ICU admission, although only rs1965708-C remained significant after conditional logistic regression adjustment for the previously mentioned variables and stratified by hospital of origin (P = 0.031; OR, 2.43) (Table 3). The same analysis remained significant at SFTPA2 haplotype 1A1 in a dominant model (P = 0.029; OR, 0.32) (Table 4). It is noteworthy that Kaplan-Meier analysis and the log-rank test showed that the variants rs1965708-C and rs1059046-A were associated with a significantly shorter time to ICU admission in hospitalized patients (Figure 3). The same analysis also showed that ICU admission was less frequently required among patients with the haplotype 1A1, and this difference was readily detected in the first days after hospitalization. The effect of these variants at the time of ICU admission remained significant in Cox regression.

Figure 3
figure 3

Kaplan-Meier estimation of days until ICU admission in hospitalized H1N1pdm-infected patients according to SFTPA2 variants. Only those comparisons with P < 0.05 were included. Solid curves represent the most frequent variant under study, and the dotted curves, the rest of variants. Significance levels calculated by means of log-rank test and Cox regression stratified by hospital of origin and adjusted for the variables age, gender, risk factors, secondary bacterial pneumonia and bacteremia are shown at the bottom of the figure. HR (95% CI), hazard ratio (95% confidence interval).

Full size image

We finally evaluated the influence of genetic variants of SFTPA1 and SFTPA2 on respiratory gas exchange in 52 hospitalized patients. SFTPA2 alleles (rs1965708-C and rs1059046-A) and haplotypes (1A0) predisposing to increased severity were found to be associated with significantly lower PaO2/FiO2 ratios, independent of age, gender, risk factors, secondary bacterial pneumonia, and bacteremia (Figure 4). Interestingly, the effect of these alleles or haplotypes was found to be dependent on the number of alleles present in a genotype or diplotype: P = 0.0007, P = 0.0007 and P = 0.0004 for rs1965708-C, rs1059046-A, and 1A0 respectively. The 1A1 haplotype, which was associated with lesser severity, was also associated with higher PaO2/FiO2 ratios (P = 0.0007), and this effect was also found to be dose-dependent in a linear regression model adjusted for the same independent variables (P = 0.0014) (Figure 4).

Figure 4
figure 4

Ratio of oxygen arterial pressure to oxygen inspiratory fraction (PaO 2 /FiO 2 ) with regard to SFTPA2 genetic variants . PaO2/FiO2 with regard to alleles and haplotypes (a) as well as genotypes and diplotypes (b) of SFTPA2 in hospitalized patients with H1N1 pandemic 2009 influenza A virus infection. Each bar represents the mean ± SD. P values were calculated with a regression lineal model, including the variables age, gender, risk factors, secondary bacterial pneumonia, and bacteremia.

Full size image

Discussion

Glycosylation of hemagglutinins may be an important mechanism by which IAV can evade recognition by antibodies in an immune population. By contrast, glycosylation of hemagglutinins is important in determining sensitivity of IAV to recognition by collectins [7, 27]. SP-D and MBL bind to mannose-rich glycans on the hemagglutinins and neuraminidase glycoproteins of IAV, agglutinating viral particles and inhibiting infectivity and neuraminidase activity [7]. Among the known human collectins, SP-D has the strongest in vitro capability of aggregating and neutralizing activity of IAV [7, 12, 27]. Hemagglutinins from all available strains of pandemic influenza viruses show significantly lower glycosylation sites compared with seasonal strains; and pandemic viruses, particularly H1N1pdm, were found to be resistant to the antiviral activities of SP-D, MBL, and the pentraxin PTX3 [7, 13, 27]. We have not observed any association with severity when deficient-, low-, or high-MBL producer genotypes and SFTPD SNPs or haplotypes were compared (data not shown). Interestingly, SP-A binding to hemagglutinins and SP-A-dependent IAV neutralization in vitro are not influenced by the extent of hemagglutinins glycosylation. SP-A is slightly more effective than SP-D at neutralizing nonglycosylated IAV strains, and it neutralizes IAV strains resistant to SP-D [12].

Accordingly, our results point toward a role of SFTPA2 SNPs and haplotypes, particularly haplotypes 1A0 and 1A1, in the severity of H1N1pdm infection. The rationale for such an association seems to be the involvement of SFTPA2 variants in gas-exchange parameters, which, in the case of pulmonary IAV infection, is largely dependent on IAV-induced lung inflammation.

Besides its role in IAV neutralization, the hydrophilic SP-A and -D have been shown to have an antiinflammatory function. Binding of the carbohydrate-binding recognition domains (CRDs) to signal-inhibitory regulatory protein α (SIRPα) on alveolar macrophages suppresses NF-κB activation and inflammation, allowing the healthy lung to remain in a quiescent state. SP-A and SP-D can also inhibit inflammation, through the CRD, blocking Toll-like receptors 2 and 4. Pulmonary clearance of IAV was reduced, and pulmonary inflammation and severity were increased in Sftpa-/-mice compared with wild-type mice [10, 11]. SP-A was also found to disturb the host inflammatory response to IAV infection in mouse models without directly influencing viral growth and spread, and even without demonstrable viral binding, at least when the virus was resistant to neutralization by SP-D [9]. Insufficient amounts of surfactant, particularly SP-A, have been observed in prematurely born infants with respiratory distress syndrome (pRDS). The haplotype 1A0 or SFTPA1-SFTPA2 haplotypes containing 1A0 have been repeatedly associated with the development of pRDS, whereas SP haplotypes containing 1A1 were found to be protective against that condition [5, 15]. These findings parallel those observed in our study, suggesting that 1A0 and 1A1 might influence the inflammatory response and the severity of H1N1pdm infection without binding to IAV.

Human SP-A1 and –A2 have similar in vitro hemagglutination-inhibition activity of IAV strains exhibiting non- or poorly glycosylated hemagglutinins heads [14]. However, in all functional assays, SP-A2 is more active than SP-A1 [5, 15]. So it is not surprising that among all the genetic variants of collectins analyzed in our study, only a few alleles and haplotypes of SFTPA2 were associated with H1N1pdm severity in hospitalized patients. Furthermore, the effect of the SFTPA2 variants on the need for ICU admission was detected in the first few days of hospitalization, as would be expected for components of the innate immunity involved in inflammation and defense against IAV infection.

The significance of the functional differences between variants at SFTPA1 and SFTPA2 is poorly understood [5, 15]. The variant rs1965708 produces an amino-acid change at residue 223 (Q223K), located in the CRD of SP-A2, and might directly influence the binding properties to either IAV or the antiinflammatory receptor SIRPα. Residue 9 (rs1059046, T9N) is located in the signal peptide, and it is unknown whether this variant may affect the protein. It is, however, worth noting that haplotypes 1A0 and 1A1 differ precisely at residues 9 and 223. A role of SNPs at regulatory regions in haplotypes 1A0 and 1A1 in translation and/or RNA stability of SFTPA2 cannot be ruled out [5, 15]. Interestingly, SP-A2 1A1 variants were shown to have a lower activity for enhancement of TNF-α in macrophage-derived THP-1 cells than other variants, such as 1A and 1A0, particularly after oxidative stress [28, 29]. These data suggest that the protective effect of the SP-A2 1A1 variant in the severity of H1N1pdm infection could be due to its lower proinflammatory activity.

Irrespective of the causal SNP(s), our data suggest that the haplotype 1A0 of SFTPA2 is associated with a higher severity after H1N1pdm infection, whereas the SFTPA2 haplotype 1A1 was associated with a dominant protective effect against severe forms of H1N1pdm infection.

We acknowledge several limitations of our study. First, the overrepresentation of hospitalized patients, could bias us to analyze susceptibility to H1N1pdm infection. In addition, our control group could be considered a representative sample from the Spanish population rather than a representation of non-H1N1pdm-infected individuals.

Second, our study is underpowered to detect the role of some variants on severity of H1N1pdm infection. Nevertheless, considering odds ratios and a significance level of 5%, the power of the associations of rs1965708-C with the development of ARDS and septic shock was 84%, and more than 88% for the need for MV. In the haplotype analysis, statistical power was 88.56% for the effect of the haplotype 1A1 on ICU admission (90.62% for the effect in a dominant model). No correction for multiple comparisons was performed in these comparisons, but, as expected by in vivo and in vitro studies among the human collectins, only SP-A would be expected to influence H1N1pdm infectivity, and significant associations were repeatedly observed with several clinical phenotypes. Furthermore, the observed associations were found to be independent of age, gender, risk factors predisposing to severe H1N1 infection, and development of either secondary bacterial pneumonia or bacteremia. Variants of SFTPA2 were clearly associated with functional parameters of gas exchange, underscoring their role in the severity of H1N1pdm-induced lung injury.

Third, criteria for ICU admission may vary between different centers. To avoid these differences, multivariate and Cox regression analysis to evaluate the need for ICU admission were stratified by hospital of origin.

Conclusion

Our study suggests that variants at SFTPA2 influence the severity of H1N1pdm infection in hospitalized patients. The potential of collectins as therapeutic agents for the treatment of IAV-mediated disease is now being explored [7, 30]. In Sftpa-/-and Sftpd-/-mice, intratracheally administered SP-A or SP-D can restore microbial clearance and inflammation [5], and exogenous surfactant preparations containing the hydrophobic SP-B and -C are widely used for replacement therapies in pRDS. The data from our study, together with a better knowledge of the functional significance of the genetic variability at SFTPA2 on IAV-associated disease, could pave the way for a potential treatment with haplotype-specific (1A1) SP-A2 for patients with the most severe forms of the disease in future IAV pandemics.

Key messages

  • Genetic variation in the SFTPA2 gene influences the outcome of patients infected with the 2009 pandemic H1N1 influenza A virus.

  • Data from our study may help to identify patients at higher risk of severe pandemic (nonglycosylated) IAV infection, who may eventually benefit from more-personalized and targeted therapies.

Authors’ information

Jordi Solé-Violán and Felipe Rodríguez de Castro should be regarded as co-second last senior authors.

Abbreviations

ARDS:

Acute respiratory distress syndrome

ARF:

acute respiratory failure

BMI:

body mass index

CEIC:

ComitéÉtico de Investigación Clínica (Clinical Research Ethics Committee)

CRD:

carbohydrate recognition domain

FiO2:

fraction of inspired oxygen

H1N1pdm:

virus influenza A H1N1 pandemic

HIV:

human immunodeficiency virus

HR:

hazard ratio

IAV:

influenza A virus

ICU:

intensive care unit

MBL:

mannose-binding lectin

MODS:

multiorgan dysfunction syndrome

MV:

mechanical ventilation

NF-κB:

nuclear factor kappa B

OR:

odds ratio

PaO2:

partial pressure of oxygen

pRDS:

respiratory distress syndrome in prematurely born infant

PVP:

primary viral pneumonia

SaO2:

arterial oxygen saturation

SIRPα:

signal inhibitory regulatory protein α

SNP:

single-nucleotide polymorphism

SP:

surfactant protein.

References

  1. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362: 1708-1719.

    Article  PubMed  Google Scholar 

  2. Horby P, Nguyen NY, Dunstan SJ, Baillie JK: The role of host genetics in susceptibility to influenza: a systematic review. PLoS One 2012, 7: e33180. 10.1371/journal.pone.0033180

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Albright FS, Orlando P, Pavia AT, Jackson GG, Cannon Albright LA: Evidence for a heritable predisposition to death due to influenza. J Infect Dis 2008, 197: 18-24. 10.1086/524064

    Article  PubMed  Google Scholar 

  4. Keynan Y, Malik S, Fowke KR: The role of polymorphisms in host immune genes in determining the severity of respiratory illness caused by pandemic H1N1 influenza. Public Health Genomics 2013, 16: 9-16. 10.1159/000345937

    Article  PubMed  CAS  Google Scholar 

  5. Wright JR: Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005, 5: 58-68. 10.1038/nri1528

    Article  PubMed  CAS  Google Scholar 

  6. Eisen DP: Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun 2010, 2: 114-122. 10.1159/000228159

    Article  PubMed  CAS  Google Scholar 

  7. Ng WC, Tate MD, Brooks AG, Reading PC: Soluble host defense lectins in innate immunity to influenza virus. J Biomed Biotechnol 2012, 2012: 732191.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Selman L, Hansen S: Structure and function of collectin liver 1 (CL-L1) and collectin 11 (CL-11, CL-K1). Immunobiology 2012, 217: 851-863. 10.1016/j.imbio.2011.12.008

    Article  PubMed  CAS  Google Scholar 

  9. Hawgood S, Brown C, Edmondson J, Stumbaugh A, Allen L, Goerke J, Clark H, Poulain F: Pulmonary collectins modulate strain-specific influenza a virus infection and host responses. J Virol 2004, 78: 8565-8572. 10.1128/JVI.78.16.8565-8572.2004

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. LeVine AM, Hartshorn K, Elliott J, Whitsett J, Korfhagen T: Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am J Physiol Lung Cell Mol Physiol 2002, 282: L563-L572.

    Article  PubMed  CAS  Google Scholar 

  11. Li G, Siddiqui J, Hendry M, Akiyama J, Edmondson J, Brown C, Allen L, Levitt S, Poulain F, Hawgood S: Surfactant protein-A–deficient mice display an exaggerated early inflammatory response to a beta-resistant strain of influenza A virus. Am J Respir Cell Mol Biol 2002, 26: 277-282. 10.1165/ajrcmb.26.3.4584

    Article  PubMed  Google Scholar 

  12. Hartshorn KL, White MR, Shepherd V, Reid K, Jensenius JC, Crouch EC: Mechanisms of anti-influenza activity of surfactant proteins A and D: comparison with serum collectins. Am J Physiol 1997, 273: L1156-L1166.

    PubMed  CAS  Google Scholar 

  13. Job ER, Deng YM, Tate MD, Bottazzi B, Crouch EC, Dean MM, Mantovani A, Brooks AG, Reading PC: Pandemic H1N1 influenza A viruses are resistant to the antiviral activities of innate immune proteins of the collectin and pentraxin superfamilies. J Immunol 2010, 185: 4284-4291. 10.4049/jimmunol.1001613

    Article  PubMed  CAS  Google Scholar 

  14. Mikerov AN, White M, Hartshorn K, Wang G, Floros J: Inhibition of hemagglutination activity of influenza A viruses by SP-A1 and SP-A2 variants expressed in CHO cells. Med Microbiol Immunol 2008, 197: 9-12.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Silveyra P, Floros J: Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury. Front Biosci 2012, 17: 407-429. 10.2741/3935

    Article  CAS  Google Scholar 

  16. Haczku A: Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol 2008, 122: 861-879. 10.1016/j.jaci.2008.10.014

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Hoover RR, Floros J: Organization of the human SP-A and SP-D loci at 10q22-q23: physical and radiation hybrid mapping reveal gene order and orientation. Am J Respir Cell Mol Biol 1998, 18: 353-362. 10.1165/ajrcmb.18.3.3035

    Article  PubMed  CAS  Google Scholar 

  18. Garcia-Laorden MI, de Rodriguez CF, Sole-Violan J, Rajas O, Blanquer J, Borderias L, Aspa J, Briones ML, Saavedra P, Marcos-Ramos JA, González-Quevedo N, Sologuren I, Herrera-Ramos E, Ferrer JM, Rello J, Rodríguez-Gallego C: Influence of genetic variability at the surfactant proteins A and D in community-acquired pneumonia: a prospective, observational, genetic study. Crit Care 2011, 15: R57. 10.1186/cc10030

    Article  PubMed  PubMed Central  Google Scholar 

  19. Garcia-Laorden MI, de Rodriguez CF, Sole-Violan J, Payeras A, Briones ML, Borderias L, Aspa J, Blanquer J, Rajas O, Marcos-Ramos JA, Herrera-Ramos E, García-Bello MA, Noda J, Ferrer JM, Rello J, Rodríguez-Gallego C: The role of mannose-binding lectin in pneumococcal infection. Eur Respir J 2013, 41: 131-139. 10.1183/09031936.00174111

    Article  PubMed  CAS  Google Scholar 

  20. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644

    Article  PubMed  CAS  Google Scholar 

  21. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R, The American-European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149: 818-824. 10.1164/ajrccm.149.3.7509706

    Article  PubMed  CAS  Google Scholar 

  22. DiAngelo S, Lin Z, Wang G, Phillips S, Ramet M, Luo J, Floros J: Novel, non-radioactive, simple and multiplex PCR-cRFLP methods for genotyping human SP-A and SP-D marker alleles. Dis Markers 1999, 15: 269-281. 10.1155/1999/961430

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. The International HapMap Consortium: A haplotype map of the human genome. Nature 2005, 437: 1299-1320. 10.1038/nature04226

    Article  PubMed Central  Google Scholar 

  24. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21: 263-265. 10.1093/bioinformatics/bth457

    Article  PubMed  CAS  Google Scholar 

  25. Foreman MG, Kong X, DeMeo DL, Pillai SG, Hersh CP, Bakke P, Gulsvik A, Lomas DA, Litonjua AA, Shapiro SD, Tal-Singer R, Silverman EK: Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2011, 44: 316-322. 10.1165/rcmb.2009-0360OC

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Lingappa JR, Dumitrescu L, Zimmer SM, Lynfield R, McNicholl JM, Messonnier NE, Whitney CG, Crawford DC: Identifying host genetic risk factors in the context of public health surveillance for invasive pneumococcal disease. PLoS One 2011, 6: e23413. 10.1371/journal.pone.0023413

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Job ER, Deng YM, Barfod KK, Tate MD, Caldwell N, Reddiex S, Maurer-Stroh S, Brooks AG, Reading PC: Addition of glycosylation to influenza A virus hemagglutinin modulates antibody-mediated recognition of H1N1 2009 pandemic viruses. J Immunol 2013, 190: 2169-2177. 10.4049/jimmunol.1202433

    Article  PubMed  CAS  Google Scholar 

  28. Wang G, Umstead TM, Phelps DS, Al-Mondhiry H, Floros J: The effect of ozone exposure on the ability of human surfactant protein a variants to stimulate cytokine production. Environ Health Perspect 2002, 110: 79-84.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Mikerov AN, Umstead TM, Gan X, Huang W, Guo X, Wang G, Phelps DS, Floros J: Impact of ozone exposure on the phagocytic activity of human surfactant protein A (SP-A) and SP-A variants. Am J Physiol Lung Cell Mol Physiol 2008, 294: L121-L130.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Sato A, Whitsett JA, Scheule RK, Ikegami M: Surfactant protein-d inhibits lung inflammation caused by ventilation in premature newborn lambs. Am J Respir Crit Care Med 2010, 181: 1098-1105. 10.1164/rccm.200912-1818OC

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are grateful to the patients and their families for their trust, as well as to the healthy volunteers. We also thank Miguel Ángel García-Bello for statistical assistance, Nereida González-Quevedo for technical features, and Consuelo Ivañez for their invaluable help. We appreciate the attention given by local Ethics Committee of involved hospitals: CEIC Hospital Universitario de Gran Canaria Dr. Negrín, CEIC Hospital del Mar de Investigaciones Médicas, CEIC Hospital San Jorge, Hospital Clínico y CEIC Universitario de Valencia, and CEIC Hospital de la Princesa.

This work was supported by grants from Fondo de Investigaciones Sanitarias, Ministerio de Economía y Competitividad [PI 02/1620, 04/1190, 06/1031, 10/01718, and 12/01565] with the funding of European Regional Development Fund-European Social Fund (FEDER-FSE); RedRespira-ISCIII-RTIC-03/11; Sociedad Española de Neumología y Cirugía Torácica (SEPAR); E.H.R. and Y.F. by a grant from Universidad de Las Palmas de Gran Canaria, and M.L.R., by a grant from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad [FI 11/00593]. The sponsors of the study had no role in designing the study, collecting, analyzing, and interpreting the data, or writing the manuscript.

Author information

Authors and Affiliations

  1. Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35010, Spain

    Estefanía Herrera-Ramos, Marta López-Rodríguez, María Isabel García-Laorden, Yanira Florido & Carlos Rodríguez-Gallego

  2. Department of Medical and Surgical Sciences, School of Medicine, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, 35016, Spain

    Estefanía Herrera-Ramos, Yanira Florido, Felipe Rodríguez de Castro & Carlos Rodríguez-Gallego

  3. Department of Internal Medicine, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, 35010, Spain

    José Juan Ruíz-Hernández

  4. Department of Infectious Diseases, Hospital Universitari del Mar, Barcelona, 08003, Spain

    Juan Pablo Horcajada, Elisabeth Lerma, Milagro Montero & Luisa Sorlí

  5. Hospital del Mar de Investigaciones Médicas (IMIM), CIBERES, Barcelona, 08003, Spain

    Juan Pablo Horcajada

  6. Department of Respiratory Diseases, Hospital San Jorge, Huesca, 22004, Spain

    Luis Borderías

  7. Intensive Care Unit, Hospital Clínico y Universitario de Valencia, Valencia, 46010, Spain

    José Blanquer

  8. Department of Microbiology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35010, Spain

    María Carmen Pérez-González

  9. Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, AZ, 1105, The Netherlands

    María Isabel García-Laorden

  10. Laboratori de Referència de Catalunya, Prat de Llobrega, Barcelonat, 08820, Spain

    Virginia Mas-Bosch & Carlos Vilaplana

  11. Intensive Care Unit, Hospital Universitario de Gran Canaria Dr. Negrín, CIBERES, Las Palmas de Gran Canaria, 35010, Spain

    José María Ferrer & Jordi Solé-Violán

  12. Department of Respiratory Diseases, Hospital Universitario de la Princesa, Madrid, 28005, Spain

    Olga Rajas & Javier Aspa

  13. Department of Respiratory Diseases, Hospital Clínico y Universitario de Valencia, Valencia, 46010, Spain

    Marisa Briones

  14. Department of Immunology, Hospital La Paz, Madrid, 28046, Spain

    Eduardo López-Granados

  15. Department of Respiratory Diseases, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35010, Spain

    Felipe Rodríguez de Castro

Authors
  1. Estefanía Herrera-Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta López-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Juan Ruíz-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Pablo Horcajada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luis Borderías
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elisabeth Lerma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. José Blanquer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. María Carmen Pérez-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. María Isabel García-Laorden
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yanira Florido
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Virginia Mas-Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Milagro Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. José María Ferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Luisa Sorlí
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Carlos Vilaplana
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Olga Rajas
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Marisa Briones
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Javier Aspa
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Eduardo López-Granados
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Jordi Solé-Violán
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Felipe Rodríguez de Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Carlos Rodríguez-Gallego
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos Rodríguez-Gallego.

Additional information

Competing interests

The author(s) declare that they have no competing interests.

Authors’ contributions

EHR: acquisition, analysis, and interpretation of molecular genetic data, and statistical analysis and collaboration in the writing of the manuscript. MLR: acquisition, analysis, and interpretation of molecular genetic data and critical review of the manuscript. JJRH: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. JPH: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. LB: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. EL: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. JB: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. MCPG: acquisition, analysis, and interpretation of H1N1pdm infection data and critical review of the manuscript. MIGL: molecular genetic data acquisition, analysis, and interpretation and critical review of the manuscript. YF: molecular genetic data acquisition and critical review of the manuscript. VMB: acquisition, analysis, and interpretation of H1N1pdm infection data and critical review of the manuscript. MM: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. JMF: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. LS: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. CV: acquisition, analysis, and interpretation of H1N1pdm infection data and critical review of the manuscript. OR: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. MB: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. JA: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. ELG: acquisition, analysis, and interpretation of clinical data and critical review of the manuscript. JSV: acquisition, analysis, and interpretation of clinical data and collaboration in the writing of the manuscript. FRC: financial support, acquisition, analysis, and interpretation of clinical data and collaboration in the writing of the manuscript. CRG: coordination, conception and design, financial support, and manuscript writing. All authors read and approved the final version of the manuscript.

Authors’ original submitted files for images

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herrera-Ramos, E., López-Rodríguez, M., Ruíz-Hernández, J.J. et al. Surfactant protein A genetic variants associate with severe respiratory insufficiency in pandemic influenza A virus infection. Crit Care 18, R127 (2014). https://doi.org/10.1186/cc13934

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/cc13934

Keywords

Critical Care

ISSN: 1364-8535